London, 29-30 April
Latest News
Upcoming Events
Amphista will be attending and/or presenting at the following conferences. If you would like to meet with us, please email info@amphista.com
Protein Degradation in Focus Symposium
Dundee, 19-22 May
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Financing includes leading life-science investors Gilde Healthcare, Forbion, Novartis Venture Fund and Eli Lilly and Company Glasgow, UK, 17 March 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round. The round was co-led by Forbion and […]
Amphista Therapeutics appoints leading protein degradation pioneer, Ian Churcher as CSO
Glasgow, Scotland, 21 May 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively and efficiently, today announced the appointment of Dr Ian Churcher as Chief Scientific Officer (CSO). Amphista’s CEO Dr Nicola Thompson said, “I’m delighted to welcome Ian to the team. As an […]
Amphista Therapeutics raises $7.5 million Series A round to advance targeted protein degradation assets in cancer
Amphista’s potent bifunctional small molecules augment targeted protein degradation Investors include Advent Life Sciences, the Scottish Investment Bank, the European Investment Fund and US-based BioMotiv Glasgow, Scotland, 7 April 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins, […]